Latest News and Press Releases

FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...

FDA considered the planned HER-096 Phase 2a study design appropriateStudy design finalized; approximately 100 patients to be enrolledMore than 50% of Phase 2 funding secured or identified Espoo,...

Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter...

Herantis Pharma Plc – Press release Indivi’s digital biomarker platform is designed to enable earlier and more sensitive detection of treatment-related changes Improved sensitivity and reduced...

NeuroRPM’s AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio’s Parkinson’s disease clinical trial.

Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies...

Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma...

Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker...

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Parkinson’s Disease Treatment Market Size & Growth Outlook According to SNS Insider, the global Parkinson’s Disease Treatment Market was valued at...

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...